TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)

Onkogematologiâ

O. A. Gavrilina¹  V. E. Mamonov¹  E. N. Parovichnikova¹  A. N. Sokolov¹  L. A. Kuzmina¹  G. M. Galstyan¹  V. V. Troitskaya¹  V. G. Savchenko¹  K. I. Zarubina¹ 

[1] National Research Center for Hematology, Ministry of Health of Russia;

关键词: ph-positive acute lymphoblastic leukemia;    tyrosine kinase inhibitors;    selectivity;    combined toxicity;    t315i mutation;    imatinib;    nilotinib;    dasatinib;    axitinib;    ponatinib;    blinatumomab;   

DOI  :  10.17650/1818-8346-2017-12-3-41-49

来源: DOAJ

【 摘 要 】

A wide range of toxic complications of BCR-ABL tyrosine kinase inhibitors therapy due to non-targeted inhibition of other protein kinases. This is of particular importance in the treatment of patients with Ph-positive lymphoblastic leukemia, who receive, in addition to tyrosine kinase inhibitors, cytotoxic drugs, enhancing myelotoxicity and, as a consequence, infections and thrombo-hemorrhagic complications. In addition, complex inter-drug interactions lead to the manifestations of combined toxicity. This article presents a case report of patient with relapsed acute Ph-positive lymphoblastic leukemia, treatment of which was accompanied by numerous complications, especially during treatment of II and III generation tyrosine kinases inhibitors.

【 授权许可】

Unknown